Dacarbazine (DZ) is single drug approved by US-FDA for the treatment of a type of skin cancer melanoma. DZ have short half-life in systemic circulation as well as poor water solubility, dacarbazine laden nanocream (DZC) for the treatment of melanoma. DZC prepared by oil-in-water emulsion technique by using DZP. Dacarbazine induces programmed cell death (apoptosis) in the cancerous cells of melanoma by inhibition of synthesis of DNA. Major drawback with this drug is its poor solubility in water, short shelf life in systemic circulation, low rate of response and severe adverse effect which limit its utility. I this study dacarbazine in the form of nanoformuation (size >100nm) was utilized for augmenting the anticancer effect of chemotherapeutic drug. In current study Dacarbazine nanostructured lipid particles (DTIC-NLPs) were prepared by solvent diffusion method. cream were characterized for shape size of particle, drug loading capacity, nanoencapsulation efficacy, zeta potential, Transmission Electron Microscopy (TEM), pH value, spreadability and viscosity, In drug release study the drug shows depressed release in free form in comparison to DTIC-NLPs after 48 hrs in PBS (pH 7.4) MTT assay showed its strong cytotoxic potential as compare to simple dacarbazine suspension.